2018年AACE/ACE《2型糖尿病综合管理策略》更新与解读

2018-05-15 中国全科医学杂志.2018.21(13):7-10.

2 型糖尿病是目前全球共同面临的健康问题,美国内分泌医师协会(AACE)/ 美国内分泌学会(ACE)2018 年1 月发布的《2 型糖尿病综合管理策略》(以下简称《管理策略》)从美国的角度对其临床医生的临床实践给予指导。本文探讨该《管理策略》的核心要点及其对我国全科医生的指导意义。

中文标题:

2018年AACE/ACE《2型糖尿病综合管理策略》更新与解读

发布机构:

发布日期:

2018-05-15

简要介绍:

2 型糖尿病是目前全球共同面临的健康问题,美国内分泌医师协会(AACE)/ 美国内分泌学会(ACE)2018 年1 月发布的《2 型糖尿病综合管理策略》(以下简称《管理策略》)从美国的角度对其临床医生的临床实践给予指导。本文探讨该《管理策略》的核心要点及其对我国全科医生的指导意义。 

作者: 四川大学华西医院内分泌代谢科 李舍予

拓展指南:糖尿病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2018年AACE/ACE《2型糖尿病综合管理策略》更新与解读)] GetToolGuiderByIdResponse(projectId=1, id=c75bb1c001593e29, title=2018年AACE/ACE《2型糖尿病综合管理策略》更新与解读, enTitle=, guiderFrom=中国全科医学杂志.2018.21(13):7-10., authorId=null, author=, summary=2 型糖尿病是目前全球共同面临的健康问题,美国内分泌医师协会(AACE)/ 美国内分泌学会(ACE)2018 年1 月发布的《2 型糖尿病综合管理策略》(以下简称《管理策略》)从美国的角度对其临床医生的临床实践给予指导。本文探讨该《管理策略》的核心要点及其对我国全科医生的指导意义。 , cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Tue May 15 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>2 型糖尿病是目前全球共同面临的健康问题,美国内分泌医师协会(AACE)/ 美国内分泌学会(ACE)2018 年1 月发布的《2 型糖尿病综合管理策略》(以下简称《管理策略》)从美国的角度对其临床医生的临床实践给予指导。本文探讨该《管理策略》的核心要点及其对我国全科医生的指导意义。 </div> <div><br> </div>作者: 四川大学华西医院内分泌代谢科 李舍予 <div><br> </div> 拓展指南:<strong>与<font color=red>糖尿病</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=7fd571c001585823" title="2型糖尿病起始胰岛素后方案转换的临床指导建议" target=_blank>2型糖尿病起始胰岛素后方案转换的临床指导建议</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=ff53a1c001583341" title="社区医生2型糖尿病管理流程与分级诊疗规范(深圳专家共识)" target=_blank>社区医生2型糖尿病管理流程与分级诊疗规范(深圳专家共识)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=9bfcd1c0015686af" title="2017 RSSDI临床实践建议:2型糖尿病的管理" target=_blank>2017 RSSDI临床实践建议:2型糖尿病的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=ce39a1c00156e9b2" title="基层糖尿病微血管病变筛查与防治专家共识" target=_blank>基层糖尿病微血管病变筛查与防治专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=a82c61c00156e0c7" title="2018 HFA/ESC立场声明:2型糖尿病和心衰" target=_blank>2018 HFA/ESC立场声明:2型糖尿病和心衰</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E7%B3%96%E5%B0%BF%E7%97%85" target=_blank>有关糖尿病更多指南</a></ul>, tagList=[TagDto(tagId=2052, tagName=2型糖尿病), TagDto(tagId=50289, tagName=综合管理)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8095, appHits=1088, showAppHits=12, pcHits=5475, showPcHits=2179, likes=161, shares=37, comments=4, approvalStatus=1, publishedTime=Sun May 20 22:30:47 CST 2018, publishedTimeString=2018-05-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun May 20 22:30:47 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 21:15:02 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018年AACE/ACE《2型糖尿病综合管理策略》更新与解读)])
2018年AACE/ACE《2型糖尿病综合管理策略》更新与解读
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=883561, encodeId=b3bf88356176, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:48:59 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317537, encodeId=6dd831e53718, content=学习了.谢谢分享., beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue May 22 12:51:40 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317358, encodeId=01d131e358af, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue May 22 05:46:30 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317164, encodeId=d7f231e1641c, content=好文献学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon May 21 07:13:09 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2020-09-08 ms1000000302953060

    看看

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=883561, encodeId=b3bf88356176, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:48:59 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317537, encodeId=6dd831e53718, content=学习了.谢谢分享., beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue May 22 12:51:40 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317358, encodeId=01d131e358af, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue May 22 05:46:30 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317164, encodeId=d7f231e1641c, content=好文献学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon May 21 07:13:09 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-05-22 惠映实验室

    学习了.谢谢分享.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=883561, encodeId=b3bf88356176, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:48:59 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317537, encodeId=6dd831e53718, content=学习了.谢谢分享., beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue May 22 12:51:40 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317358, encodeId=01d131e358af, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue May 22 05:46:30 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317164, encodeId=d7f231e1641c, content=好文献学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon May 21 07:13:09 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-05-22 秀红

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=883561, encodeId=b3bf88356176, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:48:59 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317537, encodeId=6dd831e53718, content=学习了.谢谢分享., beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue May 22 12:51:40 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317358, encodeId=01d131e358af, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Tue May 22 05:46:30 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317164, encodeId=d7f231e1641c, content=好文献学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon May 21 07:13:09 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-05-21 张新亮1853311252142e2fm

    好文献学习了

    0